Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueDepreciation & Amortization (IS)EBIATGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares OutstandingShares Repurchased
Ratios

Xeris Biopharma Holdings (XERS) Other Gross PP&E Adjustments (2020 - 2026)

Xeris Biopharma Holdings filings provide 6 years of Other Gross PP&E Adjustments readings, the most recent being -$13.8 million for Q4 2025.

  • On a quarterly basis, Other Gross PP&E Adjustments rose 29.51% to -$13.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$13.8 million, a 29.51% increase, with the full-year FY2025 number at -$13.8 million, up 29.51% from a year prior.
  • Other Gross PP&E Adjustments hit -$13.8 million in Q4 2025 for Xeris Biopharma Holdings, down from -$12.2 million in the prior quarter.
  • In the past five years, Other Gross PP&E Adjustments ranged from a high of $11.0 million in Q2 2022 to a low of -$19.5 million in Q4 2024.
  • Median Other Gross PP&E Adjustments over the past 5 years was -$13.8 million (2025), compared with a mean of -$8.0 million.
  • Biggest five-year swings in Other Gross PP&E Adjustments: crashed 5426.05% in 2024 and later rose 29.51% in 2025.
  • Xeris Biopharma Holdings' Other Gross PP&E Adjustments stood at $7.6 million in 2021, then crashed by 82.28% to $1.3 million in 2022, then crashed by 1509.9% to -$18.9 million in 2023, then dropped by 2.98% to -$19.5 million in 2024, then rose by 29.51% to -$13.8 million in 2025.
  • The last three reported values for Other Gross PP&E Adjustments were -$13.8 million (Q4 2025), -$12.2 million (Q3 2025), and -$15.0 million (Q2 2025) per Business Quant data.